Structural characterization of the GSK-3β active site using selective and non-selective ATP-mimetic inhibitors

Journal of Molecular Biology

Volumn 333, Issue 2, 2003, Pages 393-407

  Bertrand, J A ^a   Thieffine, S ^a   Vulpetti, A ^a   Cristiani, C ^a   Valsasina, B ^a   Knapp, S ^a   Kalisz, H M ^a   Flocco, M ^a  

^a PFIZER INC   (United States)

Author keywords

Glycogen synthase kinase 3; Selective inhibitors; Signal transduction; Structure based design; X ray crystallography

Indexed keywords

3 ANILINO 4 ARYLMALEIMIDE INHIBITOR; ADENOSINE TRIPHOSPHATE; ALSTERPAULLONE; GLYCOGEN SYNTHASE KINASE 3 BETA; I 5; INDIRUBIN; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; STAUROSPORINE; THREONINE; UNCLASSIFIED DRUG; WATER;

ARTICLE; BINDING SITE; COMPARATIVE STUDY; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; DRUG SELECTIVITY; ENZYME ACTIVE SITE; MOLECULE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; STRUCTURE ANALYSIS;

EID: 0141645621     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2003.08.031     Document Type: Article

References (40)

1. Embi N., Rylatt D.B., Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur. J. Biochem. 107:1980;519-527.
2. Woodgett J.R. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 9:1990;2431-2438.
3. Woodgett J.R. cDNA cloning and properties of glycogen synthase kinase-3. Methods Enzymol. 200:1991;564-577.
4. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 378:1995;785-789.
5. Dominguez I., Green J.B. Missing links in GSK3 regulation. Dev. Biol. 235:2001;303-313.
6. Plyte S.E., Hughes K., Nikolakaki E., Pulverer B.J., Woodgett J.R. Glycogen synthase kinase-3: functions in oncogenesis and development. Biochim. Biophys. Acta. 1114:1992;147-162.
7. Sang H., Lu Z., Li Y., Ru B., Wang W., Chen J. Phosphorylation of tau by glycogen synthase kinase 3beta in intact mammalian cells influences the stability of microtubules. Neurosci. Letters. 312:2001;141-144.
8. Doble B.W., Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 116:2003;1175-1186.
9. Frame S., Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 359:2001;1-16.
10. Martinez A., Castro A., Dorronsoro I., Alonso M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Res. Rev. 22:2002;373-384.
11. Dajani R., Fraser E., Roe S.M., Young N., Good V., Dale T.C., Pearl L.H. Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell. 105:2001;721-732.
12. Ter Haar E., Coll J.T., Austen D.A., Hsiao H.M., Swenson L., Jain J. Structure of GSK3beta reveals a primed phosphorylation mechanism. Nature Struct. Biol. 8:2001;593-596.
13. Bax B., Carter P.S., Lewis C., Guy A.R., Bridges A., Tanner R., et al. The structure of phosphorylated GSK-3beta complexed with a peptide, FRATtide, that inhibits beta-catenin phosphorylation. Structure (Camb.). 9:2001;1143-1152.
14. Dajani R., Fraser E., Roe S.M., Yeo M., Good V.M., Thompson V., et al. Structural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complex. EMBO J. 22:2003;494-501.
15. Canagarajah B.J., Khokhlatchev A., Cobb M.H., Goldsmith E.J. Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell. 90:1997;859-869.
16. Hughes K., Nikolakaki E., Plyte S.E., Totty N.F., Woodgett J.R. Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J. 12:1993;803-808.
17. Brown N.R., Noble M.E., Endicott J.A., Johnson L.N. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nature Cell Biol. 1:1999;438-443.
18. Leclerc S., Garnier M., Hoessel R., Marko D., Bibb J.A., Snyder G.L., et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem. 276:2001;251-260.
19. Lamers M.B., Antson A.A., Hubbard R.E., Scott R.K., Williams D.H. Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine. J. Mol. Biol. 285:1999;713-725.
20. Lawrie A.M., Noble M.E., Tunnah P., Brown N.R., Johnson L.N., Endicott J.A. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nature Struct. Biol. 4:1997;796-801.
21. Prade L., Engh R.A., Girod A., Kinzel V., Huber R., Bossemeyer D. Staurosporine-induced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential. Structure. 5:1997;1627-1637.
22. Zhao B., Bower M.J., McDevitt P.J., Zhao H., Davis S.T., Johanson K.O., et al. Structural basis for Chk1 inhibition by UCN-01. J. Biol. Chem. 277:2002;46609-46615.
23. Zhu X., Kim J.L., Newcomb J.R., Rose P.E., Stover D.R., Toledo L.M., et al. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Struct. Fold. Des. 7:1999;651-661.
24. Hoessel R., Leclerc S., Endicott J.A., Nobel M.E., Lawrie A., Tunnah P., et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nature Cell Biol. 1:1999;60-67.
25. Davies T.G., Tunnah P., Meijer L., Marko D., Eisenbrand G., Endicott J.A., Noble M.E. Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate. Structure (Camb.). 9:2001;389-397.
26. Schultz C., Link A., Leost M., Zaharevitz D.W., Gussio R., Sausville E.A., et al. Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J. Med. Chem. 42:1999;2909-2919.
27. Gussio R., Zaharevitz D.W., McGrath C.F., Pattabiraman N., Kellogg G.E., Schultz C., et al. Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition. Anticancer Drug Des. 15:2000;53-66.
28. Leost M., Schultz C., Link A., Wu Y.Z., Biernat J., Mandelkow E.M., et al. Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur. J. Biochem. 267:2000;5983-5994.
29. Coghlan M.P., Culbert A.A., Cross D.A., Corcoran S.L., Yates J.W., Pearce N.J., et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 7:2000;793-803.
30. Hers I., Tavare J.M., Denton R.M. The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity. FEBS Letters. 460:1999;433-436.
31. Smith D.G., Buffet M., Fenwick A.E., Haigh D., Ife R.J., Saunders M., et al. 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Letters. 11:2001;635-639.
32. Mohammadi M., McMahon G., Sun L., Tang C., Hirth P., Yeh B.K., et al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science. 276:1997;955-960.
33. McTigue M.A., Wickersham J.A., Pinko C., Showalter R.E., Parast C.V., Tempczyk-Russell A., et al. Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. Struct. Fold. Des. 7:1999;319-330.
34. Masaaki A., Mariko I.-S., Ikuko S., Chizuko S., Tsukasa H., Chieko O., et al. Expression, purification and crystallization of human tau-protein kinase I/glycogen synthase kinase-3[beta]. Acta Crystallog. sect. D. 56:2000;1464-1465.
35. Otwinowski Z., Minor W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. Methods in Enzymology. vol. 276:1997;Academic Press, New York, USA.
36. Jones T.A., Zou J.-Y., Cowan S.W., Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallog. sect. D. 47:1991;110-119.
37. Brünger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., et al. Crystallography and NMR System: a new software suite for macromolecular structure determination. Acta Crystallog. sect. D. 54:1998;905-921.
38. Kraulis P.J. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallog. 24:1991;946-950.
39. Merritt E.A., Bacon D.J. Raster3D: Photorealistic Molecular Graphics. Methods in Enzymology. vol. 277:1997;Academic Press, New York, USA.
40. Lee B., Richards F.M. The interpretation of protein structures: estimation of static accessibility. J. Mol. Biol. 55:1971;379-400.